RxDoctor Payments Data

Julie Lynn, MD

Ophthalmology · Hattiesburg, MSNPI 1134234453

Payments from drug & device makers

$423in general payments, 2019–2025

Across 12 payments — averaging $35.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$282
  • Argenx US, Inc.$31
  • Carl Zeiss Meditec, Inc.$23
  • Johnson & Johnson Surgical Vision, Inc.$21
  • Dompe US, Inc.$21
  • Oyster Point Pharma, Inc.$17
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$423 in reported general payments places this provider in the 30th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$276,965
Medicare patients
780
Services billed
2,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine287$396,807
XiidraLifitegrast127$155,539
Cyclosporine96$76,861
TyrvayaVarenicline Tartrate47$50,632
LumiganBimatoprost104$49,804
MieboPerfluorohexyloctane/Pf28$38,764
EysuvisLoteprednol Etabonate44$21,353
CombiganBrimonidine Tartrate/Timolol60$19,141
Prednisolone Acetate461$14,113
Travoprost55$10,407
Latanoprost595$9,908
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol57$8,653
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat290$6,674
Alphagan PBrimonidine Tartrate15$6,554
Ketorolac Tromethamine311$5,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$17$50,63247 claims
AlconSimbrinza$282$3,87316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →